n°212

February 2020

Issue Contents
Editorial

Free  "Big data": big business?

p.31

Marketing Authorisations

Baclofen (Baclocur°) and alcohol dependence

p.33-36
At moderate doses, a modest aid in controlling alcohol consumption

Inset. Baclofen: risky at high doses

p.35

Pembrolizumab (Keytruda°) with cytotoxic drugs in metastatic lung cancer 

p.37-38
A useful first-line combination when PD-L1 expression is low

Durvalumab (Imfinzi°) as "maintenance" treatment for locally advanced lung cancer

p.39-40
Increased chance of survival at three years

Benralizumab and severe asthma

p.41

Fingolimod and multiple sclerosis in patients aged 10 years and older

p.41

Sirolimus and sporadic lymphangioleiomyomatosis

p.41

INN Common stem: -gatran

p.42

INN Common stem: -olol, -alol

p.42

Adverse Effects

Free  High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants

p.43

Oral peanut desensitisation: excessive adverse effects

p.44

NSAIDs: serious infections

p.44

Modafinil: congenital malformations

p.45

SSRI antidepressants: persistent sexual dysfunction

p.45

Tenoxicam: too many serious cutaneous and gastrointestinal adverse effects

p.46

Drug-induced psoriasis

p.47

Drug-induced Dupuytren's contracture

p.47

Reviews

Severe vomiting with dehydration during 
pregnancy

p.48-49
Antiemetics have little place

Inset. Antiemetic drugs to avoid during pregnancy

p.49

Influenza and vaccination of healthy subjects

p.50
Very limited efficacy

Outlook

Free  Towards better patient care: drugs to avoid in 2020

p.51-53

Free  Inset. Main changes in the 2020 update

p.53

 Queries and Comments. Interactions between ulipristal and hormonal contraception: what is the evidence?

p.54-55

Masthead

Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe